GERN Live signals | Maximize Profits with Getagraph.com

BUY 99765 min ago

@ $2.11

Issued: 14 Feb 2024 @ 13:33

Return: 65.88%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -2.09 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies...

Stats
Today's Volume	10.38M
Average Volume	12.77M
Market Cap	2.06B
EPS	$0 ( 2024-02-28 )
Next earnings date	( $-0.100 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.94
ATR14	$0.0110 (0.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-14	Feller Faye	Buy	750 000	Employee Stock Option (Right to Buy)
2024-02-14	Kapur Anil	Buy	750 000	Employee Stock Option (Right to Buy)
2024-02-14	Samuels Scott Alan	Buy	850 000	Employee Stock Option (Right to Buy)
2024-02-14	Robertson Michelle	Buy	850 000	Employee Stock Option (Right to Buy)
2024-02-14	Grethlein Andrew J	Buy	1 200 000	Employee Stock Option (Right to Buy)

INSIDER POWER
80.22
Last 95 transactions
Buy: 25 935 774 \| Sell: 3 922 187

Volume Correlation

Long: -0.31 (neutral)

Short: -0.64 (weak negative)

Signal:(29.955) Neutral

Geron Corp Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Geron Corp Correlation - Currency/Commodity

0.54
( weak )

0.75
( moderate )

0.00
( neutral )

0.64
( weak )

0.00
( neutral )

0.05
( neutral )

Geron Corp Financials

Annual	2023
Revenue:	$237 000
Gross Profit:	$-795 999 (-335.86 %)
EPS:	$-0.320

Q4	2023
Revenue:	$23 000.00
Gross Profit:	$-218 000 (-947.83 %)
EPS:	$-0.0874

Q3	2023
Revenue:	$164 000
Gross Profit:	$-29.26M (-17 842.68 %)
EPS:	$-0.0773

Q2	2023
Revenue:	$29 000.00
Gross Profit:	$-246 000 (-848.28 %)
EPS:	$-0.0899

Financial Reports:

No articles found.

Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.